2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatment
2018
A rare case of visceral leishmaniasis in an immunocompetent traveler returning to the United States from Europe
Haque L, Villanueva M, Russo A, Yuan Y, Lee EJ, Topal J, Podoltsev N. A rare case of visceral leishmaniasis in an immunocompetent traveler returning to the United States from Europe. PLOS Neglected Tropical Diseases 2018, 12: e0006727. PMID: 30286207, PMCID: PMC6171829, DOI: 10.1371/journal.pntd.0006727.Peer-Reviewed Case Reports and Technical NotesConceptsVisceral leishmaniasisHealthy travelersRare caseEndemic areasEndemic visceral leishmaniasisSuccessful initial treatmentLiposomal amphotericin BBone marrow biopsyImmunocompetent adultsImmunocompetent travelersNight sweatsImmunocompetent individualsInitial treatmentMarrow biopsyRelapseAmphotericin BPreventive measuresLeishmaniasisTreatmentUnited StatesExtensive experiencePancytopeniaSplenomegalyBiopsyPatients
2016
Selecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2016, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaTreatment-related mortalityInduction chemotherapyComplete remissionInitial treatmentMyeloid leukemiaNovel agentsOlder adultsMedian overall survivalGroup of patientsPhase III developmentDisease-related characteristicsMechanism of actionCPX-351Overall survivalLow-intensity treatmentClinical trialsTreatment outcomesPatientsRemissionChemotherapyLeukemiaMortalityTreatmentAdults